Pages that link to "Q70114212"
Jump to navigation
Jump to search
The following pages link to Structure of lactacystin, a new microbial metabolite which induces differentiation of neuroblastoma cells (Q70114212):
Displaying 50 items.
- Lactacystin (Q6468907) (← links)
- Structure and functions of the 20S and 26S proteasomes (Q24328777) (← links)
- Omuralide and vibralactone: differences in the proteasome- β-lactone-γ-lactam binding scaffold alter target preferences (Q27687714) (← links)
- Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin (Q28300614) (← links)
- The ubiquitin-proteasome pathway and proteasome inhibitors (Q28367002) (← links)
- Differential subcellular recruitment of monoacylglycerol lipase generates spatial specificity of 2-arachidonoyl glycerol signaling during axonal pathfinding (Q28511922) (← links)
- Degradation of CFTR by the ubiquitin-proteasome pathway (Q29616142) (← links)
- Proteasome inhibitors: valuable new tools for cell biologists (Q29620573) (← links)
- Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora. (Q30764187) (← links)
- Streptomyces lactacystinicus sp. nov. and Streptomyces cyslabdanicus sp. nov., producing lactacystin and cyslabdan, respectively (Q30876760) (← links)
- Quality, not quantity: the role of natural products and chemical proteomics in modern drug discovery (Q31133947) (← links)
- Beta-lactams and their potential use as novel anticancer chemotherapeutics drugs (Q33206634) (← links)
- Copper storage diseases: Menkes, Wilsons, and cancer (Q33206636) (← links)
- Apoptolidin: induction of apoptosis by a natural product (Q33231324) (← links)
- Efficient synthesis of gamma-lactams by a tandem reductive amination/lactamization sequence (Q33323637) (← links)
- Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). (Q33363903) (← links)
- Diversity-oriented synthesis and preliminary biological screening of highly substituted five-membered lactones and lactams originating from an allyboration of aldehydes and imines (Q33392021) (← links)
- Discovery and development of the anticancer agent salinosporamide A (NPI-0052). (Q33622960) (← links)
- Generating a generation of proteasome inhibitors: from microbial fermentation to total synthesis of salinosporamide a (marizomib) and other salinosporamides (Q33836952) (← links)
- Clastosome: a subtype of nuclear body enriched in 19S and 20S proteasomes, ubiquitin, and protein substrates of proteasome. (Q33902989) (← links)
- Calcium-activated proteases are critical for refilling depleted vesicle stores in cultured sensory-motor synapses of Aplysia (Q33913116) (← links)
- Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding (Q33994984) (← links)
- Lactacystin, a proteasome inhibitor: discovery and its application in cell biology. (Q34084783) (← links)
- Proteasome inhibitors as potential novel anticancer agents (Q34086759) (← links)
- Salinosporamide Natural Products: Potent 20 S Proteasome Inhibitors as Promising Cancer Chemotherapeutics (Q34142223) (← links)
- A simple stereocontrolled synthesis of salinosporamide A. (Q34321498) (← links)
- Archaeal proteasomes: proteolytic nanocompartments of the cell (Q34418425) (← links)
- Ubiquitin proteasome pathway: implications and advances in cancer therapy (Q34446282) (← links)
- Protein-reactive natural products (Q34449212) (← links)
- The marine actinomycete genus Salinispora: a model organism for secondary metabolite discovery (Q34465208) (← links)
- Advances in and applications of proteasome inhibitors (Q34863744) (← links)
- Salinosporamides D-J from the marine actinomycete Salinispora tropica, bromosalinosporamide, and thioester derivatives are potent inhibitors of the 20S proteasome (Q34605154) (← links)
- Natural products to drugs: natural product-derived compounds in clinical trials (Q34780898) (← links)
- Ammonia synthons for the multicomponent assembly of complex gamma-lactams (Q34881042) (← links)
- Recent advances in the identification and development of 20S proteasome inhibitors (Q34948723) (← links)
- Proteasome inhibitors as therapeutic agents: current and future strategies. (Q35060923) (← links)
- Peptides with anticancer use or potential. (Q35167010) (← links)
- A beta-lactone related to lactacystin induces neurite outgrowth in a neuroblastoma cell line and inhibits cell cycle progression in an osteosarcoma cell line (Q35171318) (← links)
- Thom Award Lecture. Trends in the search for bioactive microbial metabolites (Q35302718) (← links)
- Stereospecific Total Syntheses of Proteasome Inhibitors Omuralide and Lactacystin (Q35350080) (← links)
- Sporolide B: synthetic studies (Q35399630) (← links)
- Natural compounds with proteasome inhibitory activity for cancer prevention and treatment (Q35828472) (← links)
- Selective proteasome inhibitors as anti-inflammatory agents (Q36181377) (← links)
- The expanded horizon for microbial metabolites — a review (Q36241398) (← links)
- Total synthesis of natural tert-alkylamino hydroxy carboxylic acids (Q36340508) (← links)
- Natural products inhibiting the ubiquitin-proteasome proteolytic pathway, a target for drug development (Q36447161) (← links)
- Degradation of the Met tyrosine kinase receptor by the ubiquitin-proteasome pathway (Q36565319) (← links)
- Can NF-kappaB be a target for novel and efficient anti-cancer agents? (Q36863254) (← links)
- Posttranslational regulation of cyclin D1 by retinoic acid: A chemoprevention mechanism (Q36635905) (← links)
- 20S proteasome and its inhibitors: crystallographic knowledge for drug development (Q36742369) (← links)